Oligonucleotides targeting prion diseases
First Claim
Patent Images
1. A method for the prophylaxis or treatment of a prion disease in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide, wherein said oligonucleotide provides anti-prion activity.
0 Assignments
0 Petitions
Accused Products
Abstract
Randomer phosphorothioate oligonucleotide compositions have been described that inhibit PrPc conversion to PrPcs with a high level of potency. Pharmaceutical compositions or kits containing such compounds, and methods of using such compounds in the treatment, control, or prevention of prion diseases are also described.
-
Citations
65 Claims
- 1. A method for the prophylaxis or treatment of a prion disease in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide, wherein said oligonucleotide provides anti-prion activity.
- 47. A method for reducing prion activity in a biological material in vitro, comprising contacting said material with at least one anti-prion oligonucleotide.
-
52. An anti-prion pharmaceutical composition comprising a therapeutically effective amount of at least one pharmacologically acceptable, anti-prion oligonucleotide;
- and a pharmaceutically acceptable carrier, wherein said composition is adapted for the treatment, control, or prevention of a prion disease.
- View Dependent Claims (53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)
Specification